Physician profile
Mark C Kory
NPI 1326034489
$180,015.56
in general payments reported to CMS, 2019-2025
38 companies · $40K in 2025
The $40K reported for 2025 was more than what 99% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $6,131 · 2021: $6,054 · 2022: $17K · 2023: $28K · 2024: $32K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Consulting Fee: $36K · Food and Beverage: $16K · Travel and Lodging: $8,542 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,136.62 |
| Consulting Fee | $36,252.50 |
| Food and Beverage | $16,110.81 |
| Travel and Lodging | $8,542.06 |
| Education | $237.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $44,951.96 | 2021-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $43,915.50 | 2023-2025 | Zoryve |
| Pfizer INC. | $28,477.62 | 2019-2025 | |
| Almirall LLC | $15,181.74 | 2019-2025 | Klisyri |
| Epi Health, LLC | $11,046.18 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $6,323.19 | 2022-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $4,380.82 | 2019-2025 | Arazlo, Cabtreo, Jublia |
| Ucb, INC. | $4,185.12 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $3,689.05 | 2019-2025 | |
| Galderma Laboratories, L.P. | $2,052.03 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Biofrontera INC. | $1,780.03 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Biotech, INC. | $1,692.90 | 2019-2025 | Tremfya, Remicade, Simponi |
| Journey Medical Corporation | $1,592.63 | 2019-2023 | |
| Amgen INC. | $1,565.09 | 2019-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $1,549.59 | 2022-2024 | Vtama |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.